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PThe Cardioprotective Effects of the Angiotensin-
Converting Enzyme Inhibitor Perindopril in Patients
With Stable Coronary Artery Disease Are Not
Modified by Mild to Moderate Renal Insufficiency
Insights From the EUROPA Trial
Jasper J. Brugts, MD, MSC,* Eric Boersma, PHD, MSC,* Michel Chonchol, MD,†
Jaap W. Deckers, MD, PHD,* Michel Bertrand, MD,‡ Willem J. Remme, MD, PHD,§
Roberto Ferrari, MD, PHD, Kim Fox, MD,¶ Maarten L. Simoons, MD, PHD,*
on behalf of the EUROPA Investigators
Rotterdam, the Netherlands; Denver, Colorado; Lille, France; Ferrara, Italy; and London, United Kingdom
Objectives This study sought to examine whether the cardioprotective effects of angiotensin-converting enzyme (ACE) inhibi-
tor therapy by perindopril are modified by renal function in patients with stable coronary artery disease.
Background A recent study reported that an impaired renal function identified a subgroup of patients with stable coronary
artery disease more likely to benefit from ACE inhibition therapy. In light of the growing interest in tailored ther-
apy for targeting medications to specific subgroups, remarks on the consistency of the treatment effect by ACE
inhibitors are highly important.
Methods The present study involved 12,056 patients with stable coronary artery disease without heart failure randomized to
perindopril or placebo. Estimated glomerular filtration rate (eGFR) was calculated using the abbreviated Modification
of Diet in Renal Disease equation. Cox regression analysis was used to estimate multivariable-adjusted hazard ratios.
Results The mean eGFR was 76.2 (18.1) ml/min/1.73 m2. During follow-up, the primary end point (cardiovascular death,
nonfatal myocardial infarction, or resuscitated cardiac arrest) occurred in 454 of 5,761 patients (7.9%) with eGFR
75 and in 631 of 6,295 patients (10.0%) with eGFR75. Treatment benefits of perindopril were apparent in both
patient groups either with eGFR75 (hazard ratio 0.77; 95% confidence interval 0.64 to 0.93) or eGFR75 (hazard
ratio 0.84; 95% confidence interval 0.72 to 0.98). We observed no significant interaction between renal function and
treatment benefit (p  0.47). Using different cutoff points of eGFR at the level of 60 or 90 resulted in similar trends.
Conclusions The treatment benefit of perindopril is consistent and not modified by mild to moderate renal insufficiency.
(J Am Coll Cardiol 2007;50:2148–55) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.08.029o
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ceveral clinical trials in patients with stable coronary artery
isease (CAD) have shown that inhibitors of the
ngiotensin-converting enzyme (ACE) reduce the incidence
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ccepted August 8, 2007.f cardiovascular events during long-term follow-up (1–4).
ecause these effects are apparent in both low- and
igh-risk populations, as well as in those with and
ithout preserved left ventricular function, clinical treat-
ent guidelines argue that ACE inhibitors should be
sed as routine secondary prevention for the broad group
f patients with known CAD (5). Still, it should be
ealized that absolute treatment effects in low-risk pa-
ients are modest. Because the cost effectiveness of
edications is of increasing importance, there is a rapidly
rowing interest in tailored therapy. In cardiovascular
isease, targeting ACE inhibitor therapy to specific
atient groups that are most likely to benefit is of high
linical relevance. Patients with impaired renal function
re a potential target because renal function is indepen-
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ular disease (6,7).
In a recent substudy of the PEACE (Prevention of Events
ith ACE Inhibition) trial, a significant heterogeneity in
reatment effect with trandolapril was observed in relation to
enal function (8). In patients with poor renal function, defined
s an estimated glomerular filtration rate (eGFR) below 60
l/min/1.73 m2, trandolapril was associated with a significant
eduction in all-cause mortality (27% relative risk reduction) as
ompared with placebo. In contrast, no risk reduction was
bserved in patients with higher eGFR levels. The PEACE
nvestigators concluded that, in a stable CAD population,
CE inhibition offered the best cardiovascular protection in
atients with poor renal function, which could be used as a
ubgroup to target therapy (8,9). As the treatment effect of
randolapril in the entire PEACE study was neutral (10),
etrospective analyses to define patient populations with posi-
ive ACE inhibitor effects should be regarded cautiously and
erified in comparable patient populations.
The EUROPA (European Trial on Reduction of Cardiac
vents With Perindopril) study examined the preventive
ffects of ACE inhibition in a large population of patients
ith stable CAD and preserved left ventricular function. In
ight of the growing interest in tailored therapy and the
ecent results of the PEACE trial, we examined whether
enal function modified the cardioprotective benefits of ACE
nhibition therapy by perindopril in the EUROPA study.
ethods
tudy population. The design and principal results of the
UROPA study have been reported elsewhere (2,11). In
hort, the EUROPA study was a randomized, double-blind,
ulticenter study of 12,218 patients with stable CAD
ithout overt heart failure designed to assess the effect of 8
g perindopril (n  6,110) versus placebo (n  6,108) on
he combined end point of cardiovascular death, nonfatal
yocardial infarction (MI), and resuscitated cardiac arrest.
fter a mean follow-up of 4.2 years, 8.0% of patients
andomized to perindopril and 9.9% of those randomized to
lacebo reached the primary end point, which yields a 20%
elative risk reduction with perindopril (hazard ratio [HR]
.80; 95% confidence interval [CI] 0.71 to 0.91). In the
UROPA study, a serum creatinine level 1.7 mg/dl was
n exclusion criteria; however, 30 patients (0.02%) enrolled
ith serum creatinine between 1.7 and 2.2 mg/dl. Baseline
lood samples with standardized measurements of serum
reatinine levels according to protocol were available in
2,056 patients. Written informed consent was obtained
rom all patients.
ssessment of renal function. Renal function was assessed
y eGFR using the abbreviated 4-variable Modification of
iet in Renal Disease equation (12). The dimension of all
entioned eGFR levels is in ml/min/1.73 m2.
utcome measures. The primary end point was a com-osite of cardiovascular death, nonfatal MI, and resuscitated 1ardiac arrest. Secondary end
oints were the composite of to-
al mortality, nonfatal MI, hos-
ital admission for unstable an-
ina, and cardiac arrest with
uccessful resuscitation; cardio-
ascular mortality, nonfatal MI,
nd stroke or unstable angina;
atal and nonfatal MI and unsta-
le angina; stroke; and admission
or heart failure. In addition, we
ssessed total mortality and car-
iovascular mortality as individ-
al end points. The diagnosis of MI was based on the
ecommendations of the European Society of Cardiology
nd the American College of Cardiology (13).
tatistical analysis. Summary statistics for continuous
ariables are presented as mean  1 standard deviation.
ategorical data are summarized as frequencies and per-
entages. One-way analysis of variance and Pearson chi-
quare tests were used to calculate p values. We examined
GFR as a categorical variable for the association of renal
unction and clinical outcome (45, 45 to 59.9, 60 to 74.9,
5 to 89.9, and 90 ml/min/1.73 m2). In our initial
nalyses for the relation between renal function and clinical
utcome, we confined ourselves to this clinically relevant
lassification. Still, we realize that dichotomization of a con-
inuous measure may result in loss of information. Therefore,
ll analyses were repeated with eGFR as a continuous
ariable. Because both approaches showed similar results
we found no evidence of heterogeneity in treatment effect
n relation to renal function), we present our findings of the
nalysis of renal function and treatment benefit by perindo-
ril according to a binary classification. To systematically
est the consistency of perindopril in relation to renal
unction, we have chosen 2 approaches. First, because there
s a continuous relation between eGFR and cardiovascular
isk, we divided the study population according to the
edian eGFR in our study. This resulted in 2 groups of
omparable size, which we defined as relatively preserved
eGFR 75) versus impaired (eGFR 75) renal function.
econd, from a clinical point of view, we have chosen a
utoff (also dichotomous) at an eGFR 60 or an eGFR
60 and at an eGFR90 or an eGFR90, corresponding
o the presence of chronic kidney disease or a normal renal
unction at baseline, respectively. In the literature, there is
n ongoing debate regarding which cutoff point to use. For
ompleteness and comparability, we present all treatment
ffects on all cardiovascular end points at different cutoff
oints of eGFR, namely 60, 75, and 90 ml/min/1.73 m2.
ecause of numerous studies reporting that the increased
isk of cardiovascular events is already apparent at the
arliest stages of renal insufficiency, well above 60 ml/min/
.73 m2, we confined ourselves to the cutoff at 75 ml/min/
Abbreviations
and Acronyms
ACE  angiotensin-
converting enzyme
CAD  coronary artery
disease
CI  confidence interval
eGFR  estimated
glomerular filtration rate
HR  hazard ratio
MI  myocardial infarction.73 m2 for our main analyses (14–16).
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Benefit of Perindopril Not Modified by Renal Function November 27, 2007:2148–55The incidence of the primary and secondary end points
ver time was studied using the Kaplan-Meier method.
ifferences in incidence according to renal function were
valuated by log-rank tests. Absolute risk differences were
alculated until 4 years of follow-up; after that Kaplan-
eier estimates became increasingly unstable because of the
mall number of patients at risk.
Univariable and multivariable Cox proportional hazards
egression analyses were applied to examine the association
etween renal function and study end points. In multivari-
ble analysis, we adjusted for the following (potentially)
onfounding baseline characteristics: age, gender, systolic
lood pressure, diastolic blood pressure, presence of diabetes
ellitus, hypercholesterolemia, current smoking, history of
AD (MI, percutaneous coronary intervention, coronary
rtery bypass graft surgery). Interaction between renal func-
ion and treatment effect was analyzed in a continuous as
ell as a categorical model for eGFR. Each model was tested
or interaction and included an [renal function  treatment
roup] interaction term. The assumption of proportional
azards was assessed by visual judgment of the log-minus-log
urvival plots. All measures of association are presented as
ultivariable-adjusted HRs together with 95% CIs. All anal-
ses were based on intention to treat. Statistical tests were
-sided, and a value of p  0.05 was considered significant.
e used SPSS statistical software (version 12.01 for Windows,
PSS Inc., Chicago, Illinois) for our calculations.
esults
atients. The distribution of eGFR in the EUROPA trial
s presented in Figure 1. The mean eGFR in our study
opulation was 76.2  18.1 (median 74.2, interquartile
ange 64.6 to 85.2) ml/min/1.73 m2, corresponding to a
ean serum creatinine of 1.1  0.2 mg/dl. A total of 6,295
52.1%) patients had impaired renal function (eGFR 75).
aseline characteristics are shown in Table 1. Patients with
ower eGFR were older and more often were female.
urthermore, patients with impaired renal function were
ore likely to have a higher frequency of comorbidities
ncluding hypertension and diabetes mellitus, but less often
eported current smoking. Baseline characteristics for pa-
ients randomized for treatment with perindopril or placebo
ere in balance in the subjects considered in the analysis of
reatment benefits and yielded no clinically relevant
ifferences.
enal function and clinical outcome. Regardless of allo-
ated treatment, renal function was significantly associated
ith clinical outcome. In patients allocated to perindopril,
ach 10 ml/min/1.73 m2 decrease in eGFR was related to an
.7% (HR 1.09, 95% CI 1.03 to 1.15, p  0.005) increased
isk in the primary end point. A similar increased risk was
ound in those allocated to placebo: 6.5% (HR 1.06, 95% CI
.02% to 1.12%, p  0.015). With worsening eGFR
ategories, the associated HRs increased considerably for all
nd points in both treatment groups (Table 2). 1Kaplan-Meier estimates of the primary end point with
erindopril and placebo for the 2 different categories of
GFR are presented in Figure 2. Log-rank tests were
erformed for perindopril versus placebo in patients with
GFR 75 and 75, which resulted in p values of 0.005
nd 0.023, respectively.
enal function and treatment effects by perindopril. In
atients with a relatively preserved renal function, perindo-
ril was associated with a 23% (HR 0.77, 95% CI 0.64 to
.93) relative reduction in the incidence of the primary end
oint as compared with placebo. For patients with impaired
enal function, perindopril was associated with a 16%
eduction (HR 0.84, 95% CI 0.72 to 0.98). There was no
vidence of heterogeneity in the cardioprotective effect of
erindopril in relation to eGFR, when assessed as a cate-
orical (p  0.47) or as a continuous variable (p  0.37).
imilar consistencies were found for all other end points
onsidered.
The treatment effects of perindopril at the other cutoff
evels of 60 and 90 ml/min/1.73 m2 are presented in
able 3. The results were similar, and no significant
eterogeneity in treatment effect of perindopril was ob-
erved over the whole range of eGFR on all cardiovascular
nd points.
bsolute risks during follow-up. The absolute risk of the
rimary end point was highest in patients with impaired
enal function using placebo (10.3%). The absolute risk
eduction of the primary end point by perindopril at 4 years
f follow-up was 1.90% in patients with an eGFR 75 and
Figure 1 Distribution of eGFR in the EUROPA Trial
Distribution of estimated glomerular filtration rate (eGFR) in the EUROPA
trial (n  12,056). MDRD  Modification of Diet in Renal Disease equation..77% in patients with eGFR 75 (Table 4).
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November 27, 2007:2148–55 Benefit of Perindopril Not Modified by Renal FunctionFor comparability, we present the number of events of
otal mortality, cardiovascular mortality, and nonfatal MI in
he PEACE and EUROPA trials in Table 5.
iscussion
his analysis confirms that perindopril is effective in reduc-
ng cardiovascular events in patients with stable CAD
rrespective of renal function. Treatment benefit by perin-
opril is substantial and consistent in patients with and
ithout impaired renal function. Hence, renal function, as
easured by eGFR, cannot be used to select a target
opulation that will benefit most from ACE inhibition.
Regarding clinical outcome, we showed a significant
elationship with renal function. With worsening eGFR,
atients showed higher comorbidity and the associated HRs
ncreased considerably for all end points. On a continuous
cale, each 10 ml/min/1.73 m2 decrease in eGFR was
elated to a 6.5% increase in risk of the primary end point in
he placebo group. The relation between renal function and
isk of cardiovascular events has been intensively investi-
ated for several years. It has been suggested that the
ncreased risk can be explained by the co-occurrence of a
igh prevalence of baseline risk factors (17,18). However, in
aseline Characteristics of Study Population (n  12,056)
Table 1 Baseline Characteristics of Study Population (n  12,0
e
>90 75–89.9
Characteristic (n  2,131) (n  3,630)
Mean (SD) age, yrs 55.2 (9.3) 58.3 (9.1)
Gender, female 155 (7.3) 322 (8.9)
Hypertension* 472 (22.1) 926 (25.5)
Hypercholesterolemia† 1,288 (60.4) 2,312 (63.6)
Diabetes mellitus 232 (10.9) 411 (11.3)
Current smoking 469 (22.0) 626 (17.2)
Peripheral vessel disease 130 (6.1) 236 (6.5)
Previous stroke/TIA 47 (2.2) 91 (2.5)
History of CAD
MI 1,444 (67.8) 2,359 (64.9)
PCI 637 (29.9) 1,107 (30.5)
CABG 514 (24.1) 1,011 (27.8)
Medication
Platelet inhibitors 1,965 (92.2) 3,386 (93.2)
Lipid-lowering agents 1,134 (53.2) 2,040 (56.2)
Beta-blockers 1,299 (60.9) 2,269 (62.5)
Calcium antagonists 624 (29.3) 1,130 (31.1)
Nitrates 960 (45.0) 1,553 (42.8)
Diuretics 139 (6.5) 237 (6.5)
Mean (SD) systolic blood
pressure, mm Hg
134.5 (14.2) 136.3 (15.2)
Mean (SD) diastolic blood
pressure, mm Hg
82.0 (8.1) 81.8 (8.2)
Mean (SD) eGFR 104.1 (18.3) 81.7 (4.2)
Randomized to perindopril 1,060 (49.7) 1,809 (49.8)
alues are n (%) unless otherwise noted. *Blood pressure 160/95 mm Hg or receiving antihype
CABG  coronary artery bypass grafting; CAD  coronary artery disease; eGFR  estimated glo
oronary intervention; TIA  transient ischemic attack.ur study, the observed relationships remained significant efter multivariable analysis including these factors. Another
xplanation may be that renal function is a marker of
ngoing or pre-existing atherosclerosis starting in the small-
st vessels at the glomerulus, explaining the increased risk of
ubjects with only mildly decreased renal function (16–18).
Regarding the observed treatment effect, we showed that
erindopril reduced events in all patients with stable CAD
egardless of the level of renal function. The relative
eduction in the incidence of the primary end point by
erindopril was somewhat better for patients with relatively
reserved renal function. However, CIs were overlapping
nd we observed no significant interaction between treat-
ent and renal function.
A recent substudy of the PEACE trial investigated the
elationship between renal function and the effectiveness of
CE inhibition therapy in stable CAD (8). In that study,
atients with an eGFR 60 showed a significant treatment
ffect of trandolapril on total mortality, but not on the other
tudied end points nor in patients with better levels of renal
unction. The investigators observed a significant heteroge-
eity in treatment effect in relation to renal function. The
nconsistency of the treatment effect of trandolapril was
ainly related to the lack of benefit in patients with an
ml/min/1.73 m2)
60–74.9 45.0–59.9 <45
(n  4,378) (n  1,756) (n  161) p Value
61.5 (8.5) 65.1 (7.9) 69.1 (6.7) 0.01
678 (15.5) 516 (29.4) 94 (58.4) 0.01
1218 (27.8) 610 (34.7) 64 (39.8) 0.01
2,815 (64.2) 1,134 (64.5) 94 (58.4) 0.02
529 (12.1) 277 (15.8) 31 (19.3) 0.01
538 (12.3) 180 (10.2) 17 (10.6) 0.01
328 (7.5) 161 (9.2) 18 (11.2) 0.01
165 (3.8) 96 (5.5) 10 (6.2) 0.01
2,771 (63.3) 1,130 (64.3) 113 (70.2) 0.01
1,259 (28.8) 475 (27.0) 37 (23.0) 0.03
1,408 (32.2) 556 (31.6) 55 (34.2) 0.01
4,039 (92.3) 1,589 (90.4) 140 (87.0) 0.01
2,492 (56.9) 1,002 (57.0) 79 (49.1) 0.02
2,781 (63.5) 1,128 (64.2) 96 (59.6) 0.18
1,428 (32.6) 647 (36.8) 73 (45.3) 0.01
1,917 (43.8) 846 (48.1) 82 (50.9) 0.01
467 (10.6) 325 (18.5) 49 (30.4) 0.01
138.0 (15.8) 139.5 (15.8) 143.5 (17.5) 0.01
81.8 (8.1) 81.4 (8.4) 80.5 (9.0) 0.08
68.0 (4.2) 54.5 (3.9) 40.9 (4.4) 0.01
2,189 (50.0) 906 (51.6) 72 (44.7) 0.46
e treatment. †Cholesterol 6.5 mmol/l or receiving lipid-lowering treatment.
r filtration rate; GFR  glomerular filtration rate; MI  myocardial infarction; PCI  percutaneous56)
GFR (
rtensivGFR 60. Therefore, they concluded that an impaired
MC
s
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Table 2 Multivariable-Adjusted Hazard Ratios for Baseline Renal Function and Clinical Outcome (n  12,056)
Placebo (n  6,027) Perindopril (n  6,029)
End Points eGFR Events/Total HR (95% CI) Events/Total HR (95% CI)
Primary end point (cardiovascular death, nonfatal
MI, resuscitated cardiac arrest)
Reference 8.6 1.00 6.7 1.00
75–89.9 9.1 1.03 (0.80–1.33) 6.9 1.00 (0.74–1.34)
60–74.9 10.1 1.13 (0.88–1.46) 8.0 1.10 (0.83–1.46)
45–59.9 12.3 1.31 (0.97–1.76) 11.4 1.53 (1.10–2.11)
45 15.7 1.59 (0.88–2.86) 15.3 1.86 (0.96–3.60)
Total mortality, AMI, UAP, or cardiac arrest Reference 16.0 1.00 12.5 1.00
75–89.9 15.4 0.92 (0.76–1.11) 13.1 1.00 (0.80–1.23)
60–74.9 17.3 1.00 (0.83–1.20) 15.1 1.09 (0.88–1.34)
45–59.9 20.7 1.15 (0.92–1.43) 18.8 1.31 (1.03–1.66)
45 29.2 1.57 (1.01–2.42) 29.2 1.86 (1.15–3.01)
Cardiovascular mortality, AMI, and stroke Reference 9.2 1.00 7.1 1.00
75–89.9 10.0 1.04 (0.82–1.33) 8.0 1.08 (0.81–1.43)
60–74.9 11.4 1.18 (0.93–1.50) 9.1 1.16 (0.89–1.53)
45–59.9 13.3 1.30 (0.98–1.73) 12.9 1.61 (1.18–2.19)
45 19.1 1.77 (1.03–3.04) 18.1 1.99 (1.08–3.69)
Cardiovascular mortality, AMI Reference 8.4 1.00 6.7 1.00
7589.9 9.0 1.05 (0.81–1.35) 6.9 0.99 (0.74–1.33)
60–74.9 10.0 1.15 (0.89–1.48) 8.0 1.10 (0.82–1.46)
45–59.9 12.1 1.31 (0.97–1.77) 11.2 1.50 (1.09–2.08)
45 15.7 1.62 (0.90–2.93) 15.3 1.86 (0.96–3.60)
Cardiovascular mortality, AMI, and UAP Reference 13.4 1.00 10.5 1.00
75–89.9 12.9 0.93 (0.76–1.15) 11.2 1.04 (0.83–1.32)
60–74.9 14.8 1.06 (0.86–1.30) 12.6 1.13 (0.90–1.42)
45–59.9 18.1 1.26 (0.99–1.60) 15.5 1.38 (1.06–1.80)
45 23.6 1.58 (0.98–2.56) 23.6 2.00 (1.18–3.41)
Fatal and nonfatal AMI and UAP Reference 10.0 1.00 8.2 1.00
75–89.9 11.1 1.10 (0.87–1.40) 9.8 1.17 (0.90–1.52)
60–74.9 12.4 1.24 (0.98–1.56) 9.7 1.14 (0.89–1.48)
45–59.9 13.3 1.33 (1.00–1.76) 11.8 1.42 (1.05–1.91)
45 19.2 1.88 (1.10–3.21) 15.3 1.82 (0.95–3.48)
Fatal and nonfatal AMI Reference 4.9 1.00 4.4 1.00
75–89.9 7.2 1.47 (1.07–2.03) 5.4 1.20 (0.84–1.70)
60–74.9 7.3 1.54 (1.12–2.12) 4.7 1.03 (0.72–1.47)
45–59.9 7.1 1.46 (0.99–2.16) 7.3 1.65 (1.11–2.45)
45 9.0 1.82 (0.84–3.94) 6.9 1.56 (0.60–4.03)
Total mortality Reference 6.6 1.00 4.8 1.00
75–89.9 5.5 0.74 (0.54–0.99) 4.8 0.86 (0.61–1.22)
60–74.9 6.7 0.80 (0.59–1.05) 6.5 1.04 (0.75–1.45)
45–59.9 9.5 0.94 (0.67–1.31) 8.8 1.23 (0.85–1.78)
45 14.6 1.28 (0.69–2.40) 16.7 1.72 (0.88–2.33)
Cardiovascular mortality Reference 4.0 1.00 2.6 1.00
75–89.9 2.8 0.64 (0.43–0.96) 2.7 0.93 (0.58–1.47)
60–74.9 4.2 0.86 (0.59–1.24) 3.8 1.22 (0.78–1.89)
45–59.9 6.2 1.06 (0.69–1.62) 5.3 1.49 (0.91–2.45)
45 9.0 1.32 (0.60–2.94) 9.7 2.11 (0.88–5.05)
Stroke Reference 1.3 1.00 0.7 1.00
75–89.9 1.2 0.79 (0.40–1.54) 1.4 1.74 (0.75–4.03)
60–74.9 2.1 1.16 (0.63–2.14) 1.7 1.88 (0.83–4.26)
45–59.9 1.9 0.87 (0.41–1.85) 2.8 2.45 (1.02–5.87)
45 5.6 2.13 (0.71–6.36) 2.8 1.84 (0.36–9.29)
Heart failure Reference 1.2 1.00 0.6 1.00
75–89.9 1.1 0.80 (0.40–1.62) 0.9 1.28 (0.50–3.29)
60–74.9 1.9 1.20 (0.63–2.28) 1.1 1.41 (0.57–3.50)
45–59.9 2.8 1.43 (0.70–2.91) 1.3 1.29 (0.46–3.57)
45 4.5 1.75 (0.53–5.74) 6.9 5.39 (1.52–19.1)
ox regression multivariable-adjusted hazard ratios (HRs) were adjusted for age, gender, systolic blood pressure, diastolic blood pressure, presence of diabetes mellitus, hypercholesterolemia, current
moking, and history of coronary artery disease (MI, PCI, CABG).
AMI  acute myocardial infarction; CI  confidence interval; UAP  unstable angina pectoris; other abbreviations as in Table 1.
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November 27, 2007:2148–55 Benefit of Perindopril Not Modified by Renal Functionenal function defined a subset of CAD patients more likely
o benefit from ACE inhibitor therapy for cardiovascular
rotection (8,9).
The results of the PEACE trial could not be confirmed
y our analysis. Both trials studied a population of stable
AD patients with a similar cardiovascular risk profile and
similar eGFR and gender distribution. In contrast to the
EACE trial, we have shown considerable treatment ben-
fits at different levels of renal function and no heterogeneity
n the treatment effect of perindopril. In particular, no
eterogeneity in the treatment effect was observed on total
ortality and cardiovascular mortality in contrast to the
EACE trial analysis. The direction of the treatment
enefit by ACE inhibition is different because point esti-
ates were somewhat better at higher eGFR levels, imply-
ng that the treatment effect is also present in patients with
elatively preserved renal function. The difference in direc-
ion must be considered against the background of the
verall neutral results of the main PEACE trial. Our
nalysis confirms that the treatment benefit of ACE inhi-
ition with perindopril is consistent within subgroups,
hich is in line with our prior subgroup analyses and risk
odels (2,19). The HOPE (Heart Outcome and Preven-
Figure 2 Kaplan-Meier Estimates of Primary End Point With
Perindopril and Placebo According to Baseline eGFR
Kaplan-Meier estimates of the primary end point with perindopril and placebo
for different estimated glomerular filtration rates (eGFR) during follow-up (days).
The black line corresponds to patients with an eGFR 75 using placebo, and
the dotted black line corresponds to patients with an eGFR 75 using perin-
dopril. The red line corresponds to patients with an eGFR 75 using placebo,
and the dotted red line corresponds to patients with an eGFR 75 using perin-
dopril. The X-axis represents the follow-up time in days. The Y-axis represents
the risk of the primary end point. AMI  acute myocardial infarction.ion Evaluation) and SAVE (Survival and Ventricular En- (argement) trials studied the relationship between renal
unction and treatment effect of ACE inhibition, respec-
ively ramipril and captopril, in a high-risk population
20,21). In these patients, no heterogeneity in treatment
ffect in relation to renal function was shown.
In the main study of the PEACE trial, the overall
reatment effect of trandolapril was neutral (10). The
nvestigators performed subgroup analyses for possible ex-
lanations for this neutral finding. They stated that their
tudy consisted of relatively few patients with poor renal
unction (16.3% eGFR 60). Trandolapril reduced the
ncidence of total mortality only in patients with poor renal
unction. Because of this low prevalence in the PEACE
rial, the investigators stated that this could potentially
xplain the overall neutral results. However, the distribution
f eGFR in the EUROPA trial was similar (15.9% eGFR
60). Still, the overall effect of the main EUROPA study
as in favor of ACE inhibition therapy (2). The different
esult in the PEACE trial may be explained by the fact that
he PEACE study potentially had the lowest-risk popula-
ion. Renal insufficiency could identify a higher risk sub-
roup and hence explain why the PEACE trial shows a
enefit only in this subgroup in an otherwise low-risk
opulation. However, subgroup analyses of the HOPE
nd EUROPA studies in low-risk groups showed similar
vent rates compared with those of the PEACE study,
nd in low-risk groups of the EUROPA study, perindo-
ril reduced the risk of cardiovascular mortality and
onfatal MI by 17%, contrasting with 3% in the PEACE
rial. These analyses indicate that the apparent neutral
esults of the PEACE trial may not be attributable to the
ower risk of these patients nor to the background
herapies used, but rather are related to the reduced
ower of the PEACE trial caused by greater crossover
nd shorter follow-up than in the other studies
1,2,4,10,19). In addition, the different results may be
elated to substance-specific or (target) dose-dependent
ifferences between ACE inhibitors potentially in rela-
ion to the level of renal function, which may have
esulted in suboptimal dosages (22). In the EUROPA
rial, patients were assigned to receive a relatively high
ose of perindopril (8 mg), which was achieved rapidly
nd in a high proportion of patients, whereas in the
EACE trial, trandolapril was up-titrated to the target
ose (4 mg) only 6 months after randomization. At 3
ears, target dose was achieved in 57.8% of patients in the
EACE trial and 93.0% of patients in the EUROPA
rial. Both agents are in a broadly similar ACE inhibitor
ubgroup, share chemical moieties, are lipophilic, and are
ainly excreted from the kidney and were used in doses
hat showed important pharmacologic effects. Still, with-
ut head-to-head trials it cannot be excluded that there
re pharmacologic differences between the agents, possi-
ly in relation to renal insufficiency, that are important to
heir clinical efficacy to reduce cardiovascular end points
22).
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Benefit of Perindopril Not Modified by Renal Function November 27, 2007:2148–55In an additional analysis, we investigated whether the
reatment effect of perindopril showed any differences be-
ween the renal groups in absolute risks during follow-up.
mpaired renal function was associated with higher comor-
idity, such as hypertension, and worse clinical outcome in
ur study. This may explain the small difference in absolute
isk reduction in the beginning of follow-up, in which this
roup shows a direct benefit presumably from the blood
ressure lowering effects. Still, at longer follow-up the
bsolute benefits of perindopril were the same in both
roups, which may further be related to the additional
ffects of ACE inhibitors (beyond lowering blood pressure).
he ACE inhibitors with high tissue affinity especially
mprove the angiotensin II–bradykinin balance, reduce
emodeling, improve endothelial function, and may have
ntiatherosclerotic effects (23,24).
reatment Benefit of Perindopril at Different Levels of Renal Functi
Table 3 Treatment Benefit of Perindopril at Different Levels of
eGFR 60
HR (95% CI)
Testing
Interacti
Primary end point 0.77 (0.68–0.89) 0.19
0.96 (0.74–1.24) NS
Total mortality, AMI, UAP, or cardiac arrest 0.84 (0.76–0.93) 0.48
0.92 (0.76–1.13) NS
Cardiovascular mortality, AMI, and stroke 0.79 (0.69–0.90) 0.12
1.00 (0.78–1.27) NS
Cardiovascular mortality, AMI 0.78 (0.68–0.89) 0.20
0.96 (0.74–1.24) NS
Cardiovascular mortality, AMI, and UAP 0.84 (0.75–0.93) 0.76
0.88 (0.71–1.09) NS
Fatal and nonfatal AMI, UAP 0.82 (0.73–0.93) 0.65
0.89 (0.69–1.14) NS
Fatal and nonfatal AMI 0.71 (0.61–0.84) 0.06
1.04 (0.75–1.46) NS
Total mortality 0.87 (0.74–1.03) 0.72
0.97 (0.72–1.29) NS
Cardiovascular mortality 0.86 (0.69–1.06) 0.94
0.90 (0.62–1.30) NS
Stroke 0.86 (0.62–1.18) 0.28
1.24 (0.70–2.20) NS
Heart failure 0.64 (0.44–0.92) 0.84
0.59 (0.32–1.08) NS
ox regression multivariable-adjusted HRs adjusted for age, gender, systolic blood pressure, diasto
oronary artery disease (MI, PCI, CABG). Analysis of treatment effect by perindopril at different c
orresponds to patients with an eGFR below the mentioned cutoff level for each end point (dichot
NS  not significant; other abbreviations as in Tables 1 and 2.
bsolute Risk Reduction by Perindopril for the Primary End Point (n
Table 4 Absolute Risk Reduction by Perindopril for the Primary
eGFR >75 (%)
Absolute Risk (yrs) Placebo Perindopril Ris
1 2.01 1.96
2 3.95 3.54
3 6.08 5.12
4 8.54 6.64bsolute risks during follow-up were calculated using Kaplan-Meier analysis.
eGFR estimated glomerular filtration rate.linical perspective. Remarks on the consistency of the
reatment effect of ACE inhibition in patients with stable
AD are clinically relevant. In our study, in contrast to the
EACE trial, also patients with an eGFR 60 ml/min/
.73 m2 benefited from ACE inhibition by perindopril
eGFR 60: 83.4% in the PEACE trial, 84.1% in the
UROPA trial). In patients with mild renal insufficiency,
n increased risk of cardiovascular events was already
pparent and perindopril significantly reduced cardiovas-
ular events. Therefore, the earliest stages of renal insuf-
ciency can be considered a key target for preventing the
rogression of renal disease and to decrease the risk of
ardiovascular disease, especially when we also take into
ccount the recent remarks on potential renoprotective
ffects of ACE inhibitors. We question the conclusion of
he PEACE trial to specifically target therapy to patients
 12,056)
l Function (n  12,056)
eGFR 75 eGFR 90
HR (95% CI)
Testing
Interaction HR (95% CI)
Testing
Interaction
0.77 (0.64–0.93) 0.47 0.76 (0.56–1.04) 0.71
0.84 (0.72–0.98) NS 0.82 (0.72–0.93) NS
0.83 (0.72–0.95) 0.44 0.76 (0.61–0.96) 0.30
0.89 (0.79–1.00) NS 0.88 (0.80–0.97) NS
0.79 (0.66–0.94) 0.48 0.75 (0.55–1.01) 0.51
0.86 (0.74–0.99) NS 0.84 (0.74–0.95) NS
0.77 (0.64–0.93) 0.50 0.78 (0.57–1.07) 0.81
0.84 (0.72–0.99) NS 0.82 (0.72–0.93) NS
0.83 (0.72–0.97) 0.81 0.76 (0.59–0.97) 0.41
0.86 (0.75–0.97) NS 0.86 (0.77–0.95) NS
0.86 (0.73–1.01) 0.62 0.80 (0.60–1.06) 0.85
0.82 (0.70–0.94) NS 0.84 (0.74–0.94) NS
0.79 (0.63–0.98) 0.74 0.88 (0.59–1.30) 0.45
0.75 (0.62–0.92) NS 0.75 (0.64–0.88) NS
0.80 (0.64–1.00) 0.25 0.71 (0.49–1.02) 0.24
0.97 (0.81–1.16) NS 0.93 (0.80–1.08) NS
0.81 (0.60–1.09) 0.70 0.65 (0.59–0.94) 0.32
0.91 (0.72–1.14) NS 0.91 (0.74–1.11) NS
0.89 (0.55–1.44) 0.79 0.50 (0.20–1.25) 0.51
0.96 (0.68–1.35) NS 1.00 (0.75–1.35) NS
0.65 (0.38–1.12) 0.80 0.46 (0.17–1.21) 0.16
0.61 (0.42–0.90) NS 0.65 (0.47–0.91) NS
d pressure, presence of diabetes mellitus, hypercholesterolemia, current smoking, and history of
vels of eGFR: upper line corresponds to patients with an eGFR above the cutoff level, lower line
60 or 60; 75 or 75; 90 or 90).
2,056)
Point (n  12,056)
eGFR <75 (%)
rence Placebo Perindopril Risk Difference
5 3.01 2.44 0.57
1 5.41 4.72 0.69
6 7.51 6.49 1.02
0 10.29 8.52 1.77on (n
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November 27, 2007:2148–55 Benefit of Perindopril Not Modified by Renal Functionith an eGFR 60 as the subgroup more likely to benefit
rom ACE inhibition.
Some limitations of this study can be noted. The gener-
lizability of these findings to patients with severe renal
nsufficiency is limited because numbers in the lowest eGFR
ategory were relatively small, which limits our statistical
ower to detect differences in treatment benefit in these
atients. The current analysis mainly addresses patients with
ild to moderate renal insufficiency according to the Na-
ional Kidney Foundation Kidney Disease Outcomes Qual-
ty Initiative guidelines (25). Furthermore, the eGFR levels
alculated with the Modification of Diet in Renal Disease
quation remain an estimate of the true GFR; however, it is
uperior to using the serum creatinine level or the
ockcroft-Gault equation (12). Unfortunately, we did not
ave data on microalbuminuria (26).
onclusions
he treatment benefit of perindopril is consistent and is not
odified by the level of renal function in patients with
table CAD. We observed no heterogeneity in the treat-
ent effect of perindopril in relation to mild or moderate
enal insufficiency.
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